United States Food and Drug Administration (USFDA) has classified Cipla’s Patalganga manufacturing facility as Voluntary Action Indicated (VAI). USFDA had concluded routine current Good Manufacturing Practices (cGMP) inspection at Cipla’s said facility from March 28, 2024 to April 4, 2024. On conclusion of the inspection, the company had received 6 inspectional observations in Form 483.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
